Definium Therapeutics (NASDAQ:DFTX) Trading Down 5.6% – Here’s What Happened

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price was down 5.6% on Tuesday . The stock traded as low as $37.93 and last traded at $38.01. 804,683 shares changed hands during trading, a decline of 64% from the average session volume of 2,245,351 shares. The stock had previously closed at $40.25.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Second Phase 3 success: Definium reported that its Panorama Phase 3 study of DT120 ODT met its primary endpoint in generalized anxiety disorder, with statistically significant improvements in anxiety symptoms. The result strengthens the case for the company’s LSD-based treatment and supports planned discussions with the FDA ahead of a potential 2027 regulatory filing. Definium Reports Second Phase III Success in Anxiety Disorder Program
• Positive Sentiment: Analysts remain bullish: Robert W. Baird raised its price target to $79 from $75 and maintained an “outperform” rating. Needham and HC Wainwright also reaffirmed “buy” ratings with price targets of $66 and $70, respectively, implying substantial potential upside if DT120 advances successfully.
• Positive Sentiment: Coverage characterized the Phase 3 outcome as potentially “unprecedented” anxiety data and argued that DFTX could still be undervalued despite the recent move, increasing expectations for the drug’s commercial opportunity. Definium Therapeutics After Its Phase 3 Win Still Looks Undervalued
• Neutral Sentiment: Unusually heavy put-option activity, with 6,567 puts purchased versus typical daily volume of 3,899, indicates increased hedging or bearish speculation, although it does not establish the direction of the stock.
• Negative Sentiment: After the initial rally, profit-taking and heightened expectations appear to be weighing on shares. Definium remains an unprofitable clinical-stage biotech, and regulatory, commercialization, and execution risks remain ahead of any FDA decision.

Analyst Upgrades and Downgrades

DFTX has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Wells Fargo & Company upped their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Bank of America began coverage on Definium Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target for the company. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday. Finally, Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $64.88.

Definium Therapeutics Price Performance

The firm’s fifty day moving average price is $42.92 and its 200 day moving average price is $30.49. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $4.98 billion, a PE ratio of -10.80 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In related news, insider Matthew Wiley sold 2,867 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider owned 320,571 shares of the company’s stock, valued at $14,435,312.13. This represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 67,119 shares of company stock valued at $2,887,496 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Nykredit A S purchased a new position in shares of Definium Therapeutics in the 2nd quarter worth approximately $45,000. Allworth Financial LP purchased a new stake in Definium Therapeutics during the 2nd quarter valued at $110,000. Integrated Wealth Concepts LLC bought a new stake in Definium Therapeutics in the second quarter worth $159,000. NewEdge Advisors LLC bought a new stake in Definium Therapeutics in the second quarter worth $222,000. Finally, WINTON GROUP Ltd purchased a new position in Definium Therapeutics during the second quarter worth $240,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.